BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term efficacy of TEPEZZA for the treatment of TED.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2021, after the close of market on Thursday, October 28, 2021.

PROCEPT® BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced it will report financial results for the third quarter 2021 after the market close on Thursday, November 4, 2021.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021.

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Singapore and South Korea.

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,147,590, titled “Bone Positioning and Cutting System and Method.”

Naviswiss, a Swiss-based medical technology company receives clearance from the FDA to market Naviplan in the United States.